SA
GTHX

SRH Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

SRH Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,750
Closed -$22K – 323
2022
Q3 		$22K Hold
1,750
– – 0.03% 161
2022
Q2 		$9K Sell
1,750
-500
-22% -$2.77K 0.01% 214
2022
Q1 		$17K Sell
2,250
-100
-4% -$948 0.02% 188
2021
Q4 		$24K Sell
2,350
-575
-20% -$7.33K 0.03% 167
2021
Q3 		$39K Hold
2,925
– – 0.05% 141
2021
Q2 		$64K Hold
2,925
– – 0.08% 111
2021
Q1 		$70K Hold
2,925
– – 0.1% 92
2020
Q4 		$53K Hold
2,925
– – 0.09% 108
2020
Q3 		$34K Hold
2,925
– – 0.07% 121
2020
Q2 		$71K Buy
2,925
+675
+30% +$11.2K 0.18% 67
2020
Q1 		$25K Buy
+2,250
New +$42K 0.07% 104

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

SRH Advisors's GTHX Position: Q4 2022 in Review

SRH Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 1,750 shares — an estimated $22K sold.

SRH Advisors first reported a position in GTHX in Q1 2020 and held it in 11 quarters. The position peaked at $71K in Q2 2020. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • SRH Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • SRH Advisors sold 1,750 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $22K.
  • SRH Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • SRH Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $71K in Q2 2020.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on SRH Advisors's 13F filing for Q4 2022, filed 1 Feb 2023.